A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B

Conclusion: Addition of LDT to tenofovir is safe and may be renoprotective in spontaneous reactivation of hepatitis B. Combination therapy improves survival in ACLF-B despite comparable HBV DNA suppression to tenofovir monotherapy.

http://www.saudijgastro.com/text.asp?2019/25/5/319/257327

Source: The Saudi Journal of Gastroenterology - September 25, 2019 Category: Gastroenterology Authors: Ankur Jindal Ashish Vyas Manoj Sharma Guresh Kumar Shiv K Sarin Source Type: research